Lataa...

Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives

Glioblastomas are aggressive, fast-growing primary brain tumors. After standard-of-care treatment with radiation in combination with temozolomide, the overall prognosis of newly diagnosed patients remains poor, with a 2-year survival rate of less than 20%. The remarkable survival benefit gained with...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancers (Basel)
Päätekijät: Weenink, Bas, French, Pim J., Sillevis Smitt, Peter A.E., Debets, Reno, Geurts, Marjolein
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: MDPI 2020
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7140029/
https://ncbi.nlm.nih.gov/pubmed/32235752
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12030751
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!